Ph.D., University of Washington, Biostatistics, 1989.
M.S., State University of New York at Binghamton, Mathematics, 1983.
My interests and areas of expertise are:
Design, analysis, and conduct of randomized trials
Chronic disease prevention research
Ovarian cancer, including biomarkers, screening, and risk
American Statistical Association
International Biometric Society
Society for Controlled Clinical Trials
1995-2002, Associate Member, Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Biostatistics
1989-1995, Assistant Member, Fred Hutchinson Cancer Research Center, Biostatistics, Public Health Sciences
1989-1997, Affiliate Assistant Professor, University of Washington, Public Health, Biostatistics
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects.. Breast cancer research : BCR. 16(2):R30.. 2014.
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.. European journal of cancer (Oxford, England : 1990).. 2014.
Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: Results from the Women's Health Initiative.. Gynecologic oncology. 133(1):4-10.. 2014.
Regression Calibration in Nutritional Epidemiology: Example of Fat Density and Total Energy in Relationship to Postmenopausal Breast Cancer.. American journal of epidemiology.. 2013.
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.. JAMA : the journal of the American Medical Association. 310(13):1353-68.. 2013.
Sex hormone levels and risk of breast cancer with estrogen plus progestin.. Journal of the National Cancer Institute. 105(19):1496-503.. 2013.
Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements.. American journal of obstetrics and gynecology.. 2013.
Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings.. The journal of family planning and reproductive health care / Faculty of Family Planning & Reproductive Health Care, Royal College of Obstetricians & Gynaecologists. 39(3):226-8.. 2013.
Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):387-92.. 2013.
Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy.. Obstetrics and gynecology. 121(1):172-6.. 2013.
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.. JAMA : the journal of the American Medical Association. 309(6):578-86.. 2013.
Body mass index, physical activity, and survival after endometrial cancer diagnosis: Results from the Women's Health Initiative.. Gynecologic oncology. 128(2):181-86.. 2013.
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701).. Cancer causes & control : CCC. 24(2):209-15.. 2013.
Women's Health Initiative View of Estrogen Avoidance and All-Cause Mortality.. American journal of public health. 103(12):e2.. 2013.
Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial.. Menopause (New York, N.Y.).. 2013.
Efficacy of exercise for menopausal symptoms: a randomized controlled trial.. Menopause (New York, N.Y.).. 2013.
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study.. Journal of the National Cancer Institute. 105(8):526-35.. 2013.
Use of alternative time scales in Cox proportional hazard models: implications for time-varying environmental exposures.. Statistics in medicine. 31(27):3320-3327.. 2012.
The 2010 North American Menopause Society position statement on hormone therapy goes beyond the available evidence.. Menopause (New York, N.Y.). 19(7):835-6.. 2012.
Breast tenderness after initiation of conjugated equine estrogens and mammographic density change.. Breast cancer research and treatment. 131(3):969-979.. 2012.